since the COST of Dificid was such a stumbling block in your mind, I hope today's release of economic data & benefit will help you loosen your grip on vanco as first-line treatment. The argument, which never addressed recurrences, no longer holds water...with this data I believe the hospitals and insurance companies (including the Medicare program) will conclude that the cost of using Dificid vs. vanco is financially justified. Then again, maybe you've embarked on your own economic benefit analysis and would like to share.
I saw the data well before it was presented. There are 2 major flaws with the data. (1) Ananlysis used Wholesale Acquisition Price (WAC) for analysis. Hospitals do not pay WAC pricing. Hospitals pay GPO negotiated pricing (2)Vancomycin economic analysis did not use Generic Vancomycin pricing which is dirt cheap. If you used Vancocin pricing as the comparator pricing, of course there is savings with Dificid. The devil is in the detail. I give OPTR credit for their effort in pumping up OPTR stock price with this "news".